Drug Trial Radar · NCT06555796
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
Sep 23, 2024
Primary completion
Mar 13, 2027
Study completion May 7, 2029
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Conditions
- Prostate Cancer
- High-risk Biochemical Recurrence
- High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
- Non-metastatic Castration-sensitive Prostate Cancer
Interventions
XaluritamigDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
- Number of Participants Experiencing Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
University of Minnesota Medical Center Fairview
Minneapolis, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Levine Cancer Institute
Charlotte, North Carolina
Oregon Health and Science University
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia
Cabrini Hospital
Malvern, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.